PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides or their sodium salts.
1. A conjugate comprising monomeric units linked to form a polymeric chain, wherein
(a) 60 to 99% of the monomeric units are N-(2-hydroxypropyl)methacrylamide;
(b) 1 to 25% of the monomeric units are methacryloylated hydrazones formed from an aliphatic keto group of an anthracycline cancerostatic and a methacryloylated hydrazide, wherein each methacryloylated hydrazide is independently selected from the group consisting of:
C-hydrazides of N-methacryloyl-α-amino acids, C-hydrazides of N-methacryloyl-ε-amino acids, C-hydrazides of N-methacryloyl aromatic amino acids, and C-hydrazides of oligopeptides methacryloylated on their terminal amino group; and
(c) 0.5 to 15% of the monomeric units are independently N-methacryloyl-α-amino acids, N-methacryloyl-ε-amino acids, N-methacryloyl aromatic amino acids, or oligopeptides methacryloylated on their terminal amino group; or sodium salts of any of these.
2. The conjugate of claim 1 , further comprising 0.5 to 5% of monomeric units of N-methacryloyl-α-amino acids, N-methacryloyl-ε-amino acids or N-methacryloyl-oligopeptides methacryloylated on their terminal amino group, each of said monomeric units being independently terminated by an immunoglobulin molecule.
3. The conjugate of claim 1 , further comprising 0.1 to 5% of monomeric units of enzyme-degradable N-methacryloyl oligopeptides methacryloylated on their terminal amino group, through which monomeric units on two polymer chains of the conjugate are interlinked by an alkylene diamine.
4. The conjugate of claim 1 , wherein the anthracycline cancerostatic is doxorubicin.
5. The conjugate of claim 1 , further comprising: (d) 0.5 to 10% of the monomeric units are methacryloylated hydrazides, wherein each methacryloylated hydrazide is independently selected from the group consisting of: C-hydrazides of N-methacryloyl-α-amino acids; C-hydrazides of N-methacryloyl-ε-amino acids, C-hydrazides of N-methacryloyl aromatic amino acids, and C-hydrazides of oligopeptides methacryloylated on their terminal amino group.
6. The conjugate of claim 2 of the general formula
wherein
is a schematic depiction of an immunoglobulin, and wherein the individual monomeric units are disposed in a random manner in the polymeric chain and where X is a suitable link formed by each amino acid or oligopeptide residue, x ranges from 20 to 3,000, a ranges from 1 to 750, b ranges from 1 to 450, c ranges from 1 to 450, and d ranges from 1 to 150.
7. The conjugate of claim 1 wherein each amino acid or oligopeptide is independently selected from the group consisting of: Gly, Ala, Leu, GlyGly, GlyLeuGly, GlyPheGly, GlyPheLeuGly (SEQ ID NO:1), β-alanine, ε-amino caproic acid, and p-amino benzoic acid.
8. The conjugate of claim 2 wherein the immunoglobulin molecule is selected from the group consisting of: γ-globulin, an autologous antibody, and an antibody which binds a tumor-associated antigen.
9. The conjugate of claim 3 wherein the units linking the polymeric chains are chosen from the group consisting of: GlyPheLeuGly (SEQ ID NO:1), GlyLeuGly, GlyPheGly, GlyLeuPheGly (SEQ ID NO:2).
10. A pharmaceutical composition comprising a conjugate of claim 1 .
11. A pharmaceutical composition comprising a conjugate of claim 2 .
12. The conjugate of claim 5 of the general formula
wherein the individual monomeric units are disposed in a random manner in the polymeric chain and where X is a suitable link formed by each amino acid or oligopeptide residue, x ranges from 20 to 3,000, a ranges from 1 to 750, b ranges from 1 to 450 and c ranges from 1 to 450.
13. The conjugate of claim 1 , wherein the conjugate contains 30 to 3,000 monomeric units linked to form the polymeric chain.
14. The conjugate of claim 2 , wherein the immunoglobulin molecule is a monoclonal antibody or a polyclonal antibody.
15. The conjugate of claim 8 , wherein the immunoglobulin molecule is an antibody that binds a tumor-associated antigen.
16. The conjugate of claim 15 , wherein the antibody is anti-17-1A or anti-CA 15-3.
17. The pharmaceutical composition of claim 11 , wherein the immunoglobulin molecule is an antibody which binds a tumor-associated antigen.
18. The conjugate of claim 5 , wherein the anthracycline cancerostatic is doxorubicin.
19. The conjugate of claim 5 , wherein the conjugate contains 30 to 3,000 monomeric units linked to form the polymeric chain.
20. A pharmaceutical composition, comprising a conjugate of claim 5 .